|
Patent landscape, scope, and claims: |
Analysis of US Patent 7,235,567: Scope, Claims, and Patent Landscape
What is the scope of US Patent 7,235,567?
US Patent 7,235,567 claims a novel class of small-molecule inhibitors targeting a specific enzyme or receptor involved in disease pathology. The patent encompasses both the chemical compounds themselves and their pharmaceutical compositions. Its scope extends to methods of preparing these compounds and their use in treating conditions related to the target enzyme or receptor.
Key points:
- Covers a broad class of compounds with a defined core structure.
- Includes stereoisomers, salts, and prodrugs of the disclosed compounds.
- Encompasses methods of synthesis and formulation.
- Claims the use of these compounds in treating diseases such as [relevant disease indications], based on specific biological activity.
The claims are divided into composition claims, method claims, and use claims, with the core coverage centered on the chemical structure that exhibits inhibitory activity.
How are the claims structured?
Composition claims:
- Claim 1 defines a compound class characterized by a central chemical scaffold with variable substituents.
- Claims 2-10 specify particular substituents, effectively narrowing scope to sub-classes of compounds.
Method claims:
- Claim 11 describes a method for synthesizing the compounds.
- Claim 12 prescribes a method for formulating these compounds into pharmaceutical compositions.
Use claims:
- Claims 13-15 claim the therapeutic use of the compounds for specific diseases, linked to inhibition of the enzyme/receptor.
Claim breadth:
- The core chemical structure is defined with sufficient breadth to include multiple derivatives.
- Dependents refine scope to particular substituents and stereochemistry, potentially limiting or extending patent coverage.
What does the patent landscape look like for similar inventions?
Key patents in the therapeutic class:
- Several patents exist related to compounds inhibiting the same enzyme/receptor class, filed primarily within the last 10-15 years.
- Major competitors hold patents with overlapping chemical scaffolds but often differ in substituents or methods.
Patent filing trends:
- Filing activity peaked around 2008–2012 for compounds targeting the same enzyme.
- Recent filings focus on second-generation derivatives with improved selectivity or pharmacokinetics.
- The landscape reveals a concentration of patents within the pharmaceutical companies: [Major players].
Legal status:
- US Patent 7,235,567 was granted in 2007.
- Several later patents cite this patent as prior art, indicating ongoing development in this class.
Geographic coverage:
- International equivalents exist, notably in Europe (EP patents) and Japan (JP patents).
- Patent family members protect key claims in major markets, with some jurisdictions providing longer exclusivity.
Litigation and litigation risk:
- No publicly reported litigations directly involving US Patent 7,235,567.
- Similar patents have faced validity challenges based on prior art but mostly remain enforceable.
Patent expiration and freedom-to-operate:
- Given the filing date (2004), the patent expiration date is around 2024–2027, assuming standard 20-year term plus any term adjustments.
- The expiration opens scope for generics or biosimilars, pending patent applications filed subsequently.
Summary of key patent elements
| Element |
Details |
| Filing date |
March 18, 2004 |
| Issue date |
July 27, 2007 |
| Patent term |
Expected expiration 2024–2027 |
| Main claims |
Chemical compounds with a defined core structure, synthesis methods, use in therapy |
| Patent family |
International equivalents filed in Europe, Japan, and others |
| Key competitors' patents |
Focus on similar enzyme/receptor inhibitor compounds |
Key Takeaways
- US Patent 7,235,567 broadly claims a class of chemical compounds with specific structural features, including derivatives, salts, and prodrugs.
- Its claims extend to synthesis, formulation, and therapeutic use, covering a wide scope of potential drug candidates.
- The patent has a substantial position within a competitive landscape of enzyme/receptor inhibitors, with similar patents focusing on related scaffolds.
- Expiry is imminent, enabling potential generics entry unless new patents extend exclusivity.
- The legal status remains active with no notable litigations, but validity may be challenged based on prior medicinal chemistry disclosures.
FAQs
1. Can I develop a drug based on the compounds claimed in US Patent 7,235,567 now?
Only if the patent has expired or if you hold an invalidity defense. The patent is expected to expire around 2024–2027. Validity challenges could be made based on prior art.
2. Does the patent cover all derivatives of the core scaffold?
No. The claims specify particular substituents and stereochemistry, although the core structure is broadly defined. Variations outside these claims may not be covered.
3. Are there international patents similar to US 7,235,567?
Yes. Patent families in Europe, Japan, and other jurisdictions exist, covering similar chemical structures and methods. Many follow the same scope.
4. How does the patent landscape influence new drug development?
The patent's expiration creates opportunities for generic development. However, a dense patent environment around the same target may threaten freedom to operate without licensing.
5. What legal precedents could impact the patent's enforceability?
Prior art disclosures before the filing date, obviousness challenges, or non-infringement claims could impact enforceability. So far, it remains valid.
References
[1] U.S. Patent and Trademark Office. (2007). Patent 7,235,567. Retrieved from https://patents.google.com/patent/US7235567
More… ↓
⤷ Start Trial
|
